Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

	Name of entity WEEBIT NANO LTD		
WEE			
ABN			
15 1	46 455 576		
We ((the entity) give ASX the following	information.	
	t 1 - All issues nust complete the relevant sections (attach	sheets if there is not enough space).	
1	*Class of *securities issued or to be issued	Ordinary Shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	Up to 6,603,689 Ordinary Shares	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price	To be issued pursuant to a non-renounceable entitlement offer issued at a ratio of 1 new ordinary share for each 9.5 existing shares ("Entitlement Offer")	

and dates for conversion)

Yes - Ordinary Shares issued rank pari passu with existing 4 Do the *securities rank equally in all respects from the +issue shares on issue. date with an existing +class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration \$0.39 cents per Ordinary Share 6 Purpose of the issue Up to 6,603,689 Ordinary Shares to be issued under the (If issued as consideration for Entitlement Offer. the acquisition of assets, clearly identify those assets) The Company intends to use the net proceeds raised from this issue to fund the continued development of its technology and for general working capital purposes. 6a Is the entity an *eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 28 November 2018 6b resolution under rule 7.1A was passed Not Applicable 6с Number of *securities issued without security holder approval under rule 7.1 Not Applicable 6d Number of *securities issued with security holder approval under rule 7.1A

Not Applicable 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of *securities issued Not Applicable under an exception in rule 7.2 Not Applicable 6g If *securities issued under rule 7.1A. was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. 6h Not Applicable If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity's remaining See Annexures issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 24 September 2019 *Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. Number +Class 1,597,819,895 8 Ordinary fully paid shares Number and ⁺class of all +securities quoted on ASX assuming 6,603,689 (including the +securities in shares are issued section 2 if applicable) under the **Entitlement Offer** Number +Class 9 346,091 Performance Shares - expiring 30 Number and +class of all +securities not quoted on ASX July 2021 (including the +securities in 2,000,000 Options - Exercise price \$1.5625, section 2 if applicable) expiry 1 Aug 2019 1,977,096 Options - Exercise price \$0.75, expiry 30 June 2020 1,120,000 Options - Exercise price \$0.43875, expiry 2 October 2021

180,000

Options - Exercise price \$1.3125,

expiry 12 October 2022

	Lia
Number	+Class
180,000	Options - Exercise price \$1.53125,
	expiry 12 October 2022
160,000	Options - Exercise Price \$1.565,
	expiry 15 February 2028
160,000	Options - Exercise Price \$1.445,
	expiry 1 January 2028
160,000	Exercise Price \$1.2725, expiry 5
	March 2028
800,000	Options - Exercise Price \$0.8475,
	expiry 16 October 2028
290,000	Options - Exercise Price \$1.7175,
	expiry 29 January 2028
248,000	Options - Exercise Price \$0.4286,
	expiry 14 April 2029
400,000	Options – Exercise price \$0.43875,
	expiry 1 October 2027
128,000	Performance Rights – expiring
	15 February 2028
128,000	Performance Rights – expiring
	1 January 2028
128,000	Performance Rights – expiring
	5 March 2028
480,000	Performance Rights – expiring
	1 October 2027
296,000	Performance Rights – expiring
	29 January 2028

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not Applicable

Part 2 - Pro rata issue

11	Is security holder approval	Not Applicable
	required?	11
	-	
12	Is the issue renounceable or non-	Non-renounceable
	renounceable?	
13	Ratio in which the +securities will	1 for 9.5
	be offered	
14	⁺ Class of ⁺ securities to which the	Ordinary shares
	offer relates	, , , , , , , , , , , , , , , , , , ,
15	⁺ Record date to determine	7:00pm (Sydney time) on 3 September 2019
	entitlements	(-)))

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No
17	Policy for deciding entitlements in relation to fractions	Fractions will be rounded down to the nearest whole number of shares
18	Names of countries in which the entity has security holders who will not be sent new offer documents	All countries other than Australia and New Zealand.
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	5:00pm (Sydney time) 17 September 2019.
20	Names of any underwriters	Not Applicable
21	Amount of any underwriting fee or commission	Not Applicable
22	Names of any brokers to the issue	Not Applicable
23	Fee or commission payable to the broker to the issue	Not Applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not Applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not Applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	6 September 2019
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not Applicable
28	Date rights trading will begin (if applicable)	Not Applicable

29	Date rights trading will end (if applicable)	Not Applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not Applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not Applicable
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not Applicable
33	⁺ Issue date	24 September 2019
	3 - Quotation of securities donly complete this section if you are appropriately Type of *securities (tick one) *Securities described in Part	lying for quotation of securities
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entiti	es that have ticked box 34(a)	
Addit	ional securities forming a new	class of securities
Tick to docume	indicate you are providing the informatents	ion or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	

37	A copy of any trust deed for the additional *securities			
Entiti	Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought	Not Applicable		
39	⁺ Class of ⁺ securities for which quotation is sought	Not Applicable		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Not Applicable		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	Not Applicable		
	(if issued upon conversion of another ⁺ security, clearly identify that other ⁺ security)			
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number Not Applicable	+Class	

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: <u>27 August 2019</u>

(Director/Company secretary)

Print name: Mark Licciardo == == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	1,451,467,757 Actual (58,058,710 (approximation taking into account the 1:25 share consolidation)	
Add the following:		
Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2	0	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	64,285,704 - 05/10/2018 5,714,285 - 08/10/2018 11,428,571 - 12/10/2018	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	11,285,714 – 24/12/2018	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	N/A	
"A"	1,544,182,031	
	(61,767,281 (approximation taking into account the 1:25 share consolidation))	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	231,627,305	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	1,428,571 Ordinary Shares on 05/10/2018 43,475,604 Ordinary Shares on 02/11/2018 2,130,000 Ordinary Shares on 24/12/2018	
 Under an exception in rule 7.2 		
• Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	47,034,175	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	231,627,305	
Note: number must be same as shown in Step 2		
Subtract "C"	47,034,175	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	184,593,130	

04/03/2013 Appendix 3B Page 10

(7,383,725 (approximation taking into account the 1:25 share consolidation))

[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	1,544,182,031	
Note: number must be same as shown in Step 1 of Part 1	(61,767,281 (approximation taking into account the 1:25 share consolidation))	
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	154,418,203	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	154,418,203	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in		

⁺ See chapter 19 for defined terms.

Step 3	
Total ["A" x 0.10] – "E"	154,418,203
	(6,176,728 (approximation taking into account the 1:25 share consolidation))
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.